Champions Oncology, Inc.

DB:2I3 Stock Report

Market Cap: €128.5m

Champions Oncology Management

Management criteria checks 4/4

Champions Oncology's CEO is Ronnie Morris, appointed in Jan 2017, has a tenure of 14.25 years. total yearly compensation is $400.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 6.27% of the company’s shares, worth €8.06M. The average tenure of the management team and the board of directors is 4 years and 13.6 years respectively.

Key information

Ronnie Morris

Chief executive officer

US$400.0k

Total compensation

CEO salary percentage100.0%
CEO tenure8yrs
CEO ownership6.3%
Management average tenure4yrs
Board average tenure13.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ronnie Morris's remuneration changed compared to Champions Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Oct 31 2024n/an/a

-US$598k

Jul 31 2024n/an/a

-US$3m

Apr 30 2024US$400kUS$400k

-US$7m

Jan 31 2024n/an/a

-US$10m

Oct 31 2023n/an/a

-US$10m

Jul 31 2023n/an/a

-US$8m

Apr 30 2023US$600kUS$400k

-US$5m

Jan 31 2023n/an/a

-US$3m

Oct 31 2022n/an/a

US$108k

Jul 31 2022n/an/a

US$401k

Apr 30 2022US$800kUS$400k

US$548k

Jan 31 2022n/an/a

US$219k

Oct 31 2021n/an/a

US$391k

Jul 31 2021n/an/a

US$115k

Apr 30 2021US$775kUS$375k

US$362k

Jan 31 2021n/an/a

-US$1m

Oct 31 2020n/an/a

-US$2m

Jul 31 2020n/an/a

-US$1m

Apr 30 2020US$1mUS$394k

-US$2m

Jan 31 2020n/an/a

-US$181k

Oct 31 2019n/an/a

-US$956k

Jul 31 2019n/an/a

-US$995k

Apr 30 2019US$146kUS$146k

US$128k

Jan 31 2019n/an/a

-US$251k

Oct 31 2018n/an/a

US$42k

Jul 31 2018n/an/a

-US$320k

Apr 30 2018US$244kn/a

-US$1m

Compensation vs Market: Ronnie's total compensation ($USD400.00K) is about average for companies of similar size in the German market ($USD462.36K).

Compensation vs Earnings: Ronnie's compensation has been consistent with company performance over the past year.

CEO

Ronnie Morris (58 yo)

8yrs

Tenure

US$400,000

Compensation

Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017. Dr. Morris previously served as the President and a Director of Champions Oncology, Inc. from Oc...

Leadership Team

NamePositionTenureCompensationOwnership
Ronnie Morris
CEO & Director8yrsUS$400.00k6.27%
€ 8.1m
David Miller
Chief Financial Officer7.7yrsUS$260.00k0.040%
€ 51.7k
Maria Mancini
Chief Operating Officer1.5yrsno datano data
Arthur Hanson
Vice President of Technology4.7yrsno datano data
Rachel Bunting
Vice President of Global Marketingno datano datano data
Michael Ritchie
Chief Commercial Officerno datano datano data
Karin Heidemann
Executive Vice President of Global Scientific Operations3.3yrsno datano data
Marianna Zipeto
Executive Vice President of Commercial1.5yrsno datano data

4.0yrs

Average Tenure

Experienced Management: 2I3's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ronnie Morris
CEO & Director14.3yrsUS$400.00k6.27%
€ 8.1m
Scott Tobin
Independent Director13.6yrsUS$93.30k0.22%
€ 281.4k
Joel Ackerman
Independent Chairman of the Board14.3yrsUS$116.62k7.02%
€ 9.0m
David Sidransky
Independent Lead Director17.4yrsUS$85.54k5.6%
€ 7.2m
René Bernards
Scientific Advisorno datano datano data
Manuel Hidalgo
Scientific Advisorno datano datano data
Daniel Mendelson
Independent Director11.8yrsUS$85.52k1.45%
€ 1.9m
Harvey Pass
Scientific Advisorno datano datano data
Philip Breitfeld
Independent Director8.8yrsUS$85.54k0.11%
€ 137.3k
Misti Ushio
Board Observerno datano datano data
Justin Stebbing
Scientific Advisorno datano datano data
Robert Brainin
Independent Director3.9yrsUS$82.20k0%
€ 0

13.6yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 2I3's board of directors are seasoned and experienced ( 13.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 21:56
End of Day Share Price 2024/12/13 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Champions Oncology, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul BienstockB. Riley Wealth
Matthew HewittCraig-Hallum Capital Group LLC
Paul KnightJanney Montgomery Scott LLC